Physician profile
Hardik B Bhatt
NPI 1639424849
$7,038.29
in general payments reported to CMS, 2019-2025
33 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $743 · 2021: $569 · 2022: $1,277 · 2023: $492 · 2024: $1,079 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.05 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,877.83 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $973.42 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Intuitive Surgical, INC. | $755.15 | 2022-2025 | |
| Grifols USA, LLC | $379.32 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $368.32 | 2020-2024 | Dupixent |
| Genzyme Corporation | $290.77 | 2020-2025 | |
| Abiomed | $276.03 | 2019 | |
| Insmed, INC. | $252.60 | 2021-2025 | Arikayce, Brinsupri |
| Ethicon INC. | $230.10 | 2024-2025 | Monarch Platform |
| Penumbra, INC. | $194.32 | 2023-2025 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.00 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Verona Pharma, INC. | $171.84 | 2025 | Ohtuvayre |
| Electromed, INC. | $171.72 | 2021-2025 | Smartvest |
| Inogen, INC. | $142.92 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Heartflow, INC. | $135.76 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $76.42 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Abbott Laboratories | $74.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.15 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $53.36 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $47.87 | 2019-2021 | |
| Philips North America LLC | $43.96 | 2019-2024 | (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $41.20 | 2021-2024 | Glassia |
| Novartis Pharmaceuticals Corporation | $38.93 | 2021 | |
| Mylan Specialty L.P. | $33.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.70 | 2023-2024 | Acthar |
| Shire North American Group INC | $22.77 | 2019 | |
| Genentech USA, INC. | $19.68 | 2019 | |
| Amgen INC. | $19.40 | 2022 | |
| Tactile Systems Technology INC | $17.83 | 2022 | |
| Merck Sharp & Dohme LLC | $16.71 | 2025 | Zerbaxa |
| Boston Scientific Corporation | $15.40 | 2022 | |
| Viatris Specialty LLC | $14.35 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardik Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.